Abstract

Benign paroxysmal positional vertigo (BPPV) poses a significant public health concern, affecting approximately 10% of the general population. Although considered benign, BPPV profoundly impacts quality of life. Current therapeutic maneuvers primarily focus on physical repositioning techniques, prompting exploration into pharmacological adjuncts. Vitamin D's role in calcium homeostasis and inner ear function, coupled with Betahistine's vasodilatory effects, led to the investigation of their combined efficacy in BPPV management. Materials and Methods: A one-year randomized controlled trial, enrolled 120 BPPV patients, aged 18-65 years. Participants were randomly assigned to Group A (Vitamin D supplementation + Betahistine) or Group B (Betahistine alone). Outcome measures included vertigo episode reduction, balance improvement, quality of life enhancement, and recurrence rates. Statistical analyses employed descriptive statistics, t-tests, chi-square tests, and Kaplan-Meier survival analysis.

Description